Dr Li Zhang talks to ecancer about his PROFIT study, a phase 3 clinical trial comparing the effectiveness of HR20013, a novel intravenous formulation combining an NK-1 receptor inhibitor (HRS5580) with palonosetron, against the standard fosaprepitant plus palonosetron regimen in preventing nausea and vomiting induced by cisplatin-based chemotherapy in advanced non-small cell lung cancer patients.

The study found that HR20013 combined with dexamethasone was non-inferior to fosaprepitant, palonosetron and dexamethasone, with comparable complete response rates and a similar safety profile.

Notably, HR20013+DEX showed higher efficacy in controlling symptoms during the beyond-delayed phase, particularly in the second chemotherapy cycle.